Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series
Identifieur interne : 003745 ( Main/Exploration ); précédent : 003744; suivant : 003746Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series
Auteurs : Carlos Singer [États-Unis] ; Spiridon Papapetropoulos [États-Unis] ; Manuel A. Gonzalez [États-Unis] ; Eugene L. Roberts [États-Unis] ; Abraham Lieberman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Amantadine, Amantadine (adverse effects), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Case study, Edema, Edema (drug therapy), Edema (etiology), Female, Human, Humans, Middle Aged, Motor Activity (drug effects), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Rimantadine, Rimantadine (therapeutic use), Severity of Illness Index, amantadine, edema, rimantadine.
- MESH :
- chemical , adverse effects : Amantadine, Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents, Rimantadine.
- drug effects : Motor Activity.
- drug therapy : Edema, Parkinson Disease.
- etiology : Edema.
- Aged, Female, Humans, Middle Aged, Severity of Illness Index.
Abstract
We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α‐methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine‐induced peripheral side effects. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20471
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002B34
- to stream Istex, to step Curation: 002B34
- to stream Istex, to step Checkpoint: 002151
- to stream PubMed, to step Corpus: 003086
- to stream PubMed, to step Curation: 003086
- to stream PubMed, to step Checkpoint: 002F76
- to stream Ncbi, to step Merge: 001215
- to stream Ncbi, to step Curation: 001215
- to stream Ncbi, to step Checkpoint: 001215
- to stream Main, to step Merge: 004E28
- to stream PascalFrancis, to step Corpus: 001E37
- to stream PascalFrancis, to step Curation: 000E84
- to stream PascalFrancis, to step Checkpoint: 001D25
- to stream Main, to step Merge: 005203
- to stream Main, to step Curation: 003745
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series</title><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name></author><author><name sortKey="Papapetropoulos, Spiridon" sort="Papapetropoulos, Spiridon" uniqKey="Papapetropoulos S" first="Spiridon" last="Papapetropoulos">Spiridon Papapetropoulos</name></author><author><name sortKey="Gonzalez, Manuel A" sort="Gonzalez, Manuel A" uniqKey="Gonzalez M" first="Manuel A." last="Gonzalez">Manuel A. Gonzalez</name></author><author><name sortKey="Roberts, Eugene L" sort="Roberts, Eugene L" uniqKey="Roberts E" first="Eugene L." last="Roberts">Eugene L. Roberts</name></author><author><name sortKey="Lieberman, Abraham" sort="Lieberman, Abraham" uniqKey="Lieberman A" first="Abraham" last="Lieberman">Abraham Lieberman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:132740B306A91E2D747FF284A6E34FE7F7D18916</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20471</idno><idno type="url">https://api.istex.fr/document/132740B306A91E2D747FF284A6E34FE7F7D18916/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B34</idno><idno type="wicri:Area/Istex/Curation">002B34</idno><idno type="wicri:Area/Istex/Checkpoint">002151</idno><idno type="wicri:doubleKey">0885-3185:2005:Singer C:rimantadine:in:parkinson</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15809995</idno><idno type="wicri:Area/PubMed/Corpus">003086</idno><idno type="wicri:Area/PubMed/Curation">003086</idno><idno type="wicri:Area/PubMed/Checkpoint">002F76</idno><idno type="wicri:Area/Ncbi/Merge">001215</idno><idno type="wicri:Area/Ncbi/Curation">001215</idno><idno type="wicri:Area/Ncbi/Checkpoint">001215</idno><idno type="wicri:doubleKey">0885-3185:2005:Singer C:rimantadine:in:parkinson</idno><idno type="wicri:Area/Main/Merge">004E28</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0387185</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E37</idno><idno type="wicri:Area/PascalFrancis/Curation">000E84</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001D25</idno><idno type="wicri:doubleKey">0885-3185:2005:Singer C:rimantadine:in:parkinson</idno><idno type="wicri:Area/Main/Merge">005203</idno><idno type="wicri:Area/Main/Curation">003745</idno><idno type="wicri:Area/Main/Exploration">003745</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series</title><author><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology University of Miami, School of Medicine, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Papapetropoulos, Spiridon" sort="Papapetropoulos, Spiridon" uniqKey="Papapetropoulos S" first="Spiridon" last="Papapetropoulos">Spiridon Papapetropoulos</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology University of Miami, School of Medicine, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Gonzalez, Manuel A" sort="Gonzalez, Manuel A" uniqKey="Gonzalez M" first="Manuel A." last="Gonzalez">Manuel A. Gonzalez</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology University of Miami, School of Medicine, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Roberts, Eugene L" sort="Roberts, Eugene L" uniqKey="Roberts E" first="Eugene L." last="Roberts">Eugene L. Roberts</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology University of Miami, School of Medicine, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Lieberman, Abraham" sort="Lieberman, Abraham" uniqKey="Lieberman A" first="Abraham" last="Lieberman">Abraham Lieberman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Parkinson Foundation, Miami, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-07">2005-07</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="873">873</biblScope><biblScope unit="page" to="877">877</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">132740B306A91E2D747FF284A6E34FE7F7D18916</idno><idno type="DOI">10.1002/mds.20471</idno><idno type="ArticleID">MDS20471</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amantadine</term><term>Amantadine (adverse effects)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Case study</term><term>Edema</term><term>Edema (drug therapy)</term><term>Edema (etiology)</term><term>Female</term><term>Human</term><term>Humans</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Rimantadine</term><term>Rimantadine (therapeutic use)</term><term>Severity of Illness Index</term><term>amantadine</term><term>edema</term><term>rimantadine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Rimantadine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Edema</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Edema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term><term>Etude cas</term><term>Homme</term><term>Oedème</term><term>Parkinson maladie</term><term>Rimantadine</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α‐methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine‐induced peripheral side effects. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Singer, Carlos" sort="Singer, Carlos" uniqKey="Singer C" first="Carlos" last="Singer">Carlos Singer</name></region><name sortKey="Gonzalez, Manuel A" sort="Gonzalez, Manuel A" uniqKey="Gonzalez M" first="Manuel A." last="Gonzalez">Manuel A. Gonzalez</name><name sortKey="Lieberman, Abraham" sort="Lieberman, Abraham" uniqKey="Lieberman A" first="Abraham" last="Lieberman">Abraham Lieberman</name><name sortKey="Papapetropoulos, Spiridon" sort="Papapetropoulos, Spiridon" uniqKey="Papapetropoulos S" first="Spiridon" last="Papapetropoulos">Spiridon Papapetropoulos</name><name sortKey="Roberts, Eugene L" sort="Roberts, Eugene L" uniqKey="Roberts E" first="Eugene L." last="Roberts">Eugene L. Roberts</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003745 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003745 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:132740B306A91E2D747FF284A6E34FE7F7D18916
|texte= Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series
}}
| This area was generated with Dilib version V0.6.23. |  |